These three beaten-down cancer stocks could prove to be amazing value plays.
News & Analysis: Puma Biotechnology
An analyst downgrade and a departing executive make for a bad day.
PBYI earnings call for the period ending June 30, 2019.
Investors aren't very optimistic heading into the second-quarter 2019 earnings report. Can the company prove critics wrong?
The market's shortsightedness has it missing the long-term upside at this biotech, logistics specialist, and pipeline company.
The most significant potential concern for the company's lone drug product arose.
A surprising number of patients discontinued treatment with the company's sole drug product in the first quarter of 2019.
There are risks to having only one marketed drug product.
PBYI earnings call for the period ending March 31, 2019.
Investors reacted with dismay over the terms of a license agreement.